Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tenofovir/Emtricitabine in Transgender Women on Hormones
NCT03060785Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Colon tissue tenofovir diphosphate concentration at 1 week. Started Mar 2016; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03060785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060785.